1-benzylimidazole
Star0
Identification
- Generic Name
- 1-benzylimidazole
- DrugBank Accession Number
- DB04581
- Background
1-benzylimidazole, an N-imidazole derivative, has been shown to have strong cardiotonic activity.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 158.1998
Monoisotopic: 158.08439833 - Chemical Formula
- C10H10N2
- Synonyms
- 1-benzyl-1H-imidazole
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UGlutaminyl-peptide cyclotransferase Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol 1-benzylimidazole may decrease the antihypertensive activities of Acebutolol. Aceclofenac The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Aceclofenac. Acemetacin The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Acemetacin. Acetylsalicylic acid The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with 1-benzylimidazole. Alclofenac The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Alclofenac. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as n-substituted imidazoles. These are heterocyclic compounds containing an imidazole ring substituted at position 1.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Azoles
- Sub Class
- Imidazoles
- Direct Parent
- N-substituted imidazoles
- Alternative Parents
- Benzene and substituted derivatives / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
- Substituents
- Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Heteroaromatic compound / Hydrocarbon derivative / Monocyclic benzene moiety / N-substituted imidazole / Organic nitrogen compound / Organonitrogen compound / Organopnictogen compound
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- W4C9Z5BCV7
- CAS number
- 4238-71-5
- InChI Key
- KKKDZZRICRFGSD-UHFFFAOYSA-N
- InChI
- InChI=1S/C10H10N2/c1-2-4-10(5-3-1)8-12-7-6-11-9-12/h1-7,9H,8H2
- IUPAC Name
- 1-benzyl-1H-imidazole
- SMILES
- C(N1C=CN=C1)C1=CC=CC=C1
References
- Synthesis Reference
Natsuo Sawa, Takeshi Masuda, Shozo Miura, Naoki Kano, Kazuo Kamagata, Masayuki Ito, "Process for preparation of 1-benzylimidazole compound." U.S. Patent US5021584, issued June 04, 1991.
US5021584- General References
- Mori Y, Iimura K, Hirano K: N-benzylimidazole, a potent inducer of rat liver enzymes involved in mutagenic activation of various carcinogens. Mutat Res. 1993 Jun;302(2):129-33. [Article]
- Lucas J, Chan PS, Mateja N, Cervoni P, Ronsberg MA, Lipchuck LM: 1-Benzylimidazole, a thromboxane synthetase inhibitor acutely lowers blood pressure mainly by alpha-adrenoceptor blockade in spontaneously hypertensive rats (SHR). Prostaglandins Leukot Med. 1983 Dec;12(4):409-21. [Article]
- Tuttle RS, Garcia-Minor C, Simon M: Cardiovascular effects of 1-benzylimidazole. J Pharmacol Exp Ther. 1975 Sep;194(3):624-32. [Article]
- External Links
- PubChem Compound
- 77918
- PubChem Substance
- 46506844
- ChemSpider
- 70309
- BindingDB
- 7887
- ChEMBL
- CHEMBL14192
- ZINC
- ZINC000000169811
- PDBe Ligand
- 1BN
- PDB Entries
- 2afx / 3pb9 / 5s8m / 7d1d
- MSDS
- Download (69.7 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 68-70 °C PhysProp boiling point (°C) 310 °C PhysProp logP 1.60 AVDEEF,A (1993) pKa 6.7 AVDEEF,A (1993) - Predicted Properties
Property Value Source Water Solubility 1.47 mg/mL ALOGPS logP 1.58 ALOGPS logP 1.8 Chemaxon logS -2 ALOGPS pKa (Strongest Basic) 6.47 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 17.82 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 48.52 m3·mol-1 Chemaxon Polarizability 17.07 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9565 Blood Brain Barrier + 0.983 Caco-2 permeable + 0.6674 P-glycoprotein substrate Non-substrate 0.7264 P-glycoprotein inhibitor I Non-inhibitor 0.9772 P-glycoprotein inhibitor II Non-inhibitor 0.9044 Renal organic cation transporter Inhibitor 0.5285 CYP450 2C9 substrate Non-substrate 0.8583 CYP450 2D6 substrate Non-substrate 0.8724 CYP450 3A4 substrate Non-substrate 0.8169 CYP450 1A2 substrate Inhibitor 0.7491 CYP450 2C9 inhibitor Non-inhibitor 0.7615 CYP450 2D6 inhibitor Inhibitor 0.5463 CYP450 2C19 inhibitor Non-inhibitor 0.5434 CYP450 3A4 inhibitor Non-inhibitor 0.6991 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.8173 Ames test AMES toxic 0.836 Carcinogenicity Non-carcinogens 0.9052 Biodegradation Not ready biodegradable 0.7719 Rat acute toxicity 2.4931 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8224 hERG inhibition (predictor II) Non-inhibitor 0.8281
Spectra
- Mass Spec (NIST)
- Download (7.94 KB)
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 136.6402567 predictedDarkChem Lite v0.1.0 [M-H]- 128.94899 predictedDeepCCS 1.0 (2019) [M+H]+ 137.7244567 predictedDarkChem Lite v0.1.0 [M+H]+ 131.73573 predictedDeepCCS 1.0 (2019) [M+Na]+ 136.6474567 predictedDarkChem Lite v0.1.0 [M+Na]+ 140.38078 predictedDeepCCS 1.0 (2019)
Targets
![](https://go.drugbank.com/assets/locked/DrugTargets2-682eb846d210ae4bf33ca03febccfb57bb1c61318e699b729e5df4dfab2c5b67.png)
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsGlutaminyl-peptide cyclotransferase
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Responsible for the biosynthesis of pyroglutamyl peptides. Has a bias against acidic and tryptophan residues adjacent to the N-terminal glutaminyl residue and a lack of importance of chain length a...
- Gene Name
- QPCT
- Uniprot ID
- Q16769
- Uniprot Name
- Glutaminyl-peptide cyclotransferase
- Molecular Weight
- 40876.14 Da
Drug created at September 11, 2007 17:48 / Updated at June 12, 2020 16:52